Insider Sale: Pulmonx Co. (NASDAQ: LUNG) Insider Sells 355 Shares
Insider of Pulmonx Co. (NASDAQ: LUNG) Geoffrey beran rose sold 355 shares of the company in a trade on Wednesday, December 1. The shares were sold at an average price of $ 32.73 for a total trade of $ 11,619.15. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Geoffrey Beran Rose also recently completed the following transactions:
- On Monday, November 15, Geoffrey Beran Rose sold 7,000 Pulmonx shares. The shares were sold at an average price of $ 39.94, for a total trade of $ 279,580.00.
- On Friday October 15, Geoffrey Beran Rose sold 7,000 Pulmonx shares. The shares were sold at an average price of $ 39.44, for a total trade of $ 276,080.00.
- On Wednesday September 15, Geoffrey Beran Rose sold 7,000 Pulmonx shares. The stock was sold for an average price of $ 38.12, for a total trade of $ 266,840.00.
Pulmonx shares traded down $ 0.82 on Friday, reaching $ 29.72. 376,928 shares of the company were traded for an average volume of 352,540. Pulmonx Co. has a 52 week low of $ 29.50 and a 52 week high of $ 69.48. The company has a 50-day moving average of $ 38.01 and a 200-day moving average of $ 39.85. The company has a market cap of $ 1.09 billion and a PE ratio of -24.16. The company has a debt to equity ratio of 0.07, a current ratio of 10.25 and a rapid ratio of 9.57.
Pulmonx (NASDAQ: LUNG) last released its results on Monday, November 1. The company reported ($ 0.28) earnings per share for the quarter, beating the Zacks consensus estimate ($ 0.37) by $ 0.09. Pulmonx had a negative net margin of 98.57% and a negative return on equity of 20.53%. The company posted revenue of $ 13.26 million in the quarter, compared to a consensus estimate of $ 13.36 million. During the same period of the previous year, the company earned ($ 1.37) per share. As a group, analysts expect Pulmonx Co. to post earnings per share of -1.35 for the current year.
A number of research companies have recently weighed in on LUNG. Piper Sandler lowered her target price on Pulmonx stock from $ 47.00 to $ 45.00 and set a “neutral” rating on the stock in a report released on Tuesday, November 2. Wells Fargo & Company lowered its target price on Pulmonx stock from $ 56.00 to $ 55.00 and set a “weighted” rating on the stock in a report released on Wednesday, November 3. Ultimately, Zacks investment research downgraded Pulmonx’s shares from a “buy” rating to a “conservation” rating in a report released on Saturday, November 6. Four research analysts rated the stock with a conservation rating and four issued a buy rating for the company. Based on data from MarketBeat.com, Pulmonx currently has an average rating of “Buy” and a consensus price target of $ 55.25.
Several institutional investors have recently increased or reduced their stakes in the company. Bank of New York Mellon Corp increased its position in Pulmonx shares by 8.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 82,665 shares of the company valued at $ 2,974,000 after acquiring an additional 6,706 shares during the period. Squarepoint Ops LLC increased its position in Pulmonx shares by 240.6% during the 3rd quarter. Squarepoint Ops LLC now owns 20,920 shares of the company valued at $ 753,000 after acquiring an additional 14,778 shares during the period. Thrivent Financial for Lutherans increased its stake in Pulmonx by 10.1% in the third quarter. Thrivent Financial for Lutherans now owns 365,673 shares of the company valued at $ 13,157,000 after purchasing an additional 33,644 shares during the period. Two Sigma Advisers LP purchased a new position in Pulmonx in the third quarter valued at approximately $ 230,000. Finally, Two Sigma Investments LP increased its stake in Pulmonx by 762.0% in the 3rd quarter. Two Sigma Investments LP now owns 141,372 shares of the company valued at $ 5,087,000 after purchasing an additional 124,972 shares during the period. 75.82% of the shares are held by hedge funds and other institutional investors.
Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve, a solution for bronchoscopic treatment in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation.
See also: Why is total return important?
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Pulmonx now?
Before you consider Pulmonx, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and Pulmonx was not on the list.
While Pulmonx currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here